Search research articles
Contact Us
Filters
Showing results (51-60 of 79) with videos related to
Page
of 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2018
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours
Olivier Mir, Analia Azaro, Jaime Merchan, et al.
Cancers
|
May 25, 2024
What Is a Sarcoma 'Specialist Center'? Multidisciplinary Research Finds an Answer
Roger Wilson, Denise Reinke, Gerard van Oortmerssen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 1, 2009
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type
Carlos A Torres-Cabala, Wei-Lien Wang, Jonathan Trent, et al.
Genes, Chromosomes & Cancer
|
September 13, 2025
BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study
Diego M Montoya-Cerrillo, Mark G Evans, Andrew Elliott, et al.
American Journal of Surgery
|
December 16, 2003
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
Courtney L Scaife, Kelly K Hunt, Shreyaskumar R Patel, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Cancer
|
November 17, 2005
Angiosarcoma of the breast
Stephan A Vorburger, Yan Xing, Kelly K Hunt, et al.
The Lancet. Oncology
|
April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
Jean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku, Albiruni R Abdul Razak, Ping Chi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Suzanne George, Ping Chi, Michael C Heinrich, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 79) with videos related to
Sort By:
Page
of 8
European Journal of Cancer (Oxford, England : 1990)
|
September 16, 2018
Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours
Olivier Mir, Analia Azaro, Jaime Merchan, et al.
Cancers
|
May 25, 2024
What Is a Sarcoma 'Specialist Center'? Multidisciplinary Research Finds an Answer
Roger Wilson, Denise Reinke, Gerard van Oortmerssen, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 1, 2009
Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type
Carlos A Torres-Cabala, Wei-Lien Wang, Jonathan Trent, et al.
Genes, Chromosomes & Cancer
|
September 13, 2025
BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study
Diego M Montoya-Cerrillo, Mark G Evans, Andrew Elliott, et al.
American Journal of Surgery
|
December 16, 2003
Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
Courtney L Scaife, Kelly K Hunt, Shreyaskumar R Patel, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Cancer
|
November 17, 2005
Angiosarcoma of the breast
Stephan A Vorburger, Yan Xing, Kelly K Hunt, et al.
The Lancet. Oncology
|
April 18, 2015
Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial
Jean-Yves Blay, Lin Shen, Yoon-Koo Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 18, 2020
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
Filip Janku, Albiruni R Abdul Razak, Ping Chi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 14, 2021
Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour
Suzanne George, Ping Chi, Michael C Heinrich, et al.
Page
of 8